Browse

Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

3 claims

PCSK9-targeting lipid-lowering therapies (monoclonal antibodies such as evolocumab and alirocumab, and siRNA agents such as inclisiran): their LDL-lowering efficacy, safety, and effects on cardiovascular outcomes in trials and practice, typically as add-on to statins. Not for statin therapy itself or for ezetimibe and other non-PCSK9 agents.

Randomized trials show PCSK9 inhibitors added to statin therapy reduce major cardiovascular events

VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular disease Statin therapyimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

PCSK9 inhibitors reduce cardiovascular events in statin-treated patients

VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular disease Statin therapyimportance · minorImportance 0.40, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

PCSK9 inhibitors substantially lower LDL cholesterol when added to statin therapy

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →LDL cholesterol Cardiovascular medicineimportance · settledImportance 0.15, from 0 to 1 · settled: uncontested, so low even when much depends on it. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim entirely, propose it below. A proposal is reviewed on its merits; accepted claims are matched against the graph and enter it with their reasoning on record.